{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=5", "query": { "intervention": "Abiraterone and Prednisone", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 155, "total_pages": 16, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abiraterone+and+Prednisone&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-12T11:10:29.426Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02758132", "title": "Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Denosumab", "type": "BIOLOGICAL" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1, "start_date": "2016-03-01", "completion_date": "2016-09-06", "has_results": true, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 1, "location_summary": "Honolulu, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT02758132" }, { "nct_id": "NCT06952803", "title": "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Saruparib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abiraterone + Prednisolone/Prednisone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 700, "start_date": "2025-08-06", "completion_date": "2036-04-30", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06952803" }, { "nct_id": "NCT00924469", "title": "A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Leuprolide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 58, "start_date": "2009-11", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2013-04-17", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" }, { "city": "Wenatchee", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924469" }, { "nct_id": "NCT03348670", "title": "Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Abiraterone - Usual", "type": "DRUG" }, { "name": "Abiraterone - Study", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "22 Years to 75 Years · Male only" }, "enrollment_count": 600, "start_date": "2023-08-18", "completion_date": "2026-12-28", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348670" }, { "nct_id": "NCT03012321", "title": "Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer Metastatic Castration-Resistant", "Abnormal DNA Repair", "Metastatic Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 70, "start_date": "2017-01-12", "completion_date": "2027-01-16", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 16, "location_summary": "Los Angeles, California • Tampa, Florida • Chicago, Illinois + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03012321" }, { "nct_id": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Malignancies", "Non-Small Cell Lung Cancer (NSCLC)", "Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)", "Colorectal Carcinoma (CRC)" ], "interventions": [ { "name": "AZD4635", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 313, "start_date": "2016-06-17", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 17, "location_summary": "Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Fresno", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02740985" }, { "nct_id": "NCT04477512", "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hormone Refractory Prostate Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Peripheral blood collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2021-02-19", "completion_date": "2025-09-10", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04477512" }, { "nct_id": "NCT02268175", "title": "Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Adenocarcinoma", "Prostate Cancer", "High Risk Prostate Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Leuprolide Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 75, "start_date": "2014-10", "completion_date": "2021-12", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Seattle, Washington", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02268175" }, { "nct_id": "NCT04493853", "title": "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Capivasertib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Abiraterone Acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "MALE", "summary": "18 Years to 130 Years · Male only" }, "enrollment_count": 1012, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 33, "location_summary": "Tucson, Arizona • La Jolla, California • Orange, California + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493853" }, { "nct_id": "NCT03414034", "title": "Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cardiff Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 72, "start_date": "2018-08-14", "completion_date": "2023-10-16", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-12T11:10:29.426Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03414034" } ] }